Circadian variation in hematotoxicity of the antineoplastic agent “5 Fluorouracil (5 FU)” in female rats and its relevance to chronotherapy

References

• Abdellatif AAH, Mohammed AM, Saleem I, Alsharidah M, Al Rugaie O, Ahmed F, Osman SK. 2022. Smart injectable chitosan hydrogels loaded with 5-fluorouracil for the treatment of breast cancer. Pharmaceutics. 14(3):661. doi:10.3390/pharmaceutics14030661.
   PubMed Web of Science ®Google Scholar
• Almaida-Pagan PF, Torrente M, Campos M, Provencio M, Madrid JA, Franco F, Morilla BR, Cantos B, Sousa PA, Madrid MJM, et al. 2022. Chronodisruption and ambulatory circadian monitoring in cancer patients: beyond the body clock. Curr Oncol Rep. 24(2):1‑15. doi:10.1007/s11912-021-01158-z.
   PubMed Web of Science ®Google Scholar
• Altinok A, Lévi F, Goldbeter A. 2009. Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 36(1):20–38. doi:10.1016/j.ejps.2008.10.024.
   PubMed Web of Science ®Google Scholar
• Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JH, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, et al. 2018. Clinical pharmacogenetics implementation consortium (cpic) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharm Therap. 103(2):210–216. doi:10.1002/cpt.911.
   PubMed Web of Science ®Google Scholar
• Barary M, Hosseinzadeh R, Kazemi S, Liang JJ, Mansouri R, Sio TT, Hosseini M, Moghadamnia AA. 2022. The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats. Sci Rep. 12(1):8661. doi:10.1038/s41598-022-12735-y.
   PubMed Web of Science ®Google Scholar
• Ben Cherif W, Dridi I, Aouam K, Ben-Attia M, Reinberg A, Boughattas N. 2012. Chronotolerance study of the antiepileptic drug valproic acid in mice. J Circadian Rhythms. 10:3. doi:10.1186/1740-3391-10-3.
   PubMedGoogle Scholar
• Ben-Cherif W, Dridi I, Hassine M, Ben-Attia M, Aouam K, Reinberg A, Boughattas N. 2014. Circadian haematotoxicity of the antiepileptic valproic acid in mice. J Appl Biomed. 12(1):31–38. doi:10.1016/j.jab.2013.04.001.
   Web of Science ®Google Scholar
• Berger J. 2004. Chronohaematology. J Appl Biomed. 2(4):179–185. doi:10.32725/jab.2004.021.
   Google Scholar
• Bouali I, Dridi I, Gadacha W, Zaeid S, Boughattas N, Ben-Attia M, Aouam K, Souli A. 2022. Implications of circadian dosing-time in the chronotolerance and the rhythmic delivery of the 5fluorouracil (5-Fu) in female rats and its relevance to cancer therapeutics. J Pharm Drug Deliv Res. 11(1):1000203.
   Google Scholar
• Boughattas NA, Li XM, Filipski J, Lemaigre G, Filipski E, Bouzouita K, Belhadj O, Lévi F. 1996. Modulation of cisplatin chronotoxicity related to reduced glutathione in mice. Hum Exp Toxicol. 15(7):563‑72. doi:10.1177/096032719601500703.
   PubMed Web of Science ®Google Scholar
• Cai B, Chen H, Sun H, Wan P, Sun H, Pan J. 2016. Production of immunoregulatory polysaccharides from Crassostrea hongkongensis and their positive effects as nutrition factor in modulating the effectiveness and toxicity of 5-FU chemotherapy in mice. Food Funct. 7(1):390–397. doi:10.1039/C5FO00885A.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, et al. 2006. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 28(5):678‑85. doi:10.1097/01.ftd.0000245771.82720.c7.
   Web of Science ®Google Scholar
• Ciccolini J, Milano G. 2016. Women at a disadvantage in fluorouracil treatment. JAMA Oncol. 2(6):829–830. doi:10.1001/jamaoncol.2016.1086.
   PubMed Web of Science ®Google Scholar
• Cuba LF, Salum FG, Guimarães FS, Cherubini K, Borghetti RL, Figueiredo MAZ. 2020. Cannabidiol on 5-FU-induced oral mucositis in mice. Oral Dis. 26(7):1483–1493. doi:10.1111/odi.13413.
   PubMed Web of Science ®Google Scholar
• Dridi I, Ben-Cherif W, Aouam K, Hassine M, Ben-Attia M, Reinberg A, Boughattas NA. 2013. Circadian variation in haematological toxicity of the immunosuppressive agent “Mycophenolate Mofetil” in rats. J Appl Biomed. 11(2):71‑78. doi:10.2478/v10136-012-0024-9.
   Web of Science ®Google Scholar
• Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Riviere A, Perrocheau G, Etienne MC, et al. 1998. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 4(9):2039‑2045.
   PubMed Web of Science ®Google Scholar
• Finger AM, Dibner C, Kramer A. 2020. Coupled network of the circadian clocks: a driving force of rhythmic physiology. FEBS Lett. 594(17):2734‑69. doi:10.1002/1873-3468.13898.
   PubMed Web of Science ®Google Scholar
• Fleming G, Schumm P, Friberg G, Schilsky RL, Njiaju UO, Schilsky RL. 2015. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 15(1). doi:10.1186/s12885-015-1075-6.
   PubMedGoogle Scholar
• Focan C, Kreutz F, Longrée L, Graas MP, Focan-Henrard D, Moeneclaey N, David A, Biquet JF, Materne R, Weerts J, et al. 2005. Chronothérapie associant le 5-fluorouracile, l’acide folinique, et le carboplatine en première ligne thérapeutique dans le cancer colorectal métastatique. Une étude de phase 2. Pathologie Biologie. 53(5):273‑276. doi:10.1016/j.patbio.2004.12.029.
   Google Scholar
• Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer, J-C, Marc B, Schmitt A. 2018. How can we best monitor 5-FU administration to maximize benefit to risk ratio?. Expert Opin Drug Metab Toxicol. 14(12):1303–1313.
   PubMed Web of Science ®Google Scholar
• Gowda JBH, Shankar SJ, Munisamy M, Akshatha RS, Sagar VS. 2020. Development of Ph-dependent chronomodulated delivery systems of 5-fluorouracil and oxaliplatin to treat colon cancer. Int J App Pharm. 12(5):118–130. doi:10.22159/ijap.2020v12i5.38156.
   PubMedGoogle Scholar
• Hashimoto Y, Yoshida Y, Yamada T, Aisu N, Yoshimatsu G, Yoshimura F, Hasegawa S. 2020. Current status of therapeutic drug monitoring of 5-fluorouracil prodrugs. Anticancer Res. 40(8):4655–4661. doi:10.21873/anticanres.14464.
   PubMed Web of Science ®Google Scholar
• Haus E, Smolensky MH. 1999. Biologic rhythms in the immune system. Chronobiol Int. 16(5):581–622. doi:10.3109/07420529908998730.
   PubMed Web of Science ®Google Scholar
• Hesse J, Martinelli J, Aboumanify O, Ballesta A, Relógio A. 2021. A mathematical model of the circadian clock and drug pharmacology to optimize irinotecan administration timing in colorectal cancer. Comput Struct Biotechnol J. 19:5170‑5183. doi:10.1016/j.csbj.2021.08.051.
   PubMed Web of Science ®Google Scholar
• Ismail ASA, Quinn MG, Wright MA, Ernst A, Kao V, Grogan L, Parr A, Grollman F, Kirsch IR, Grem JL. 2005. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon α-2a in adenocarcinoma of the large bowel. Oncol Rep. 13(6):1145–1152. doi:10.3892/or.13.6.1145.
   PubMed Web of Science ®Google Scholar
• John J, Kinra M, Ranadive N, Keni R, Nayak PG, Jagdale RN, Ahmed SM, Raghavendra KV, Mudgal J, Nandakumar K. 2022. Neuroprotective effect of Mulmina Mango against chemotherapy-induced cognitive decline in mouse model of mammary carcinoma. Sci Rep. 12(1):3072. doi:10.1038/s41598-022-06862-9.
   PubMed Web of Science ®Google Scholar
• Khedhaier A, Ben Attia M, Gadacha W, Sani M, Bouzouita K, Chouchane L, Mechkouri M, Reinberg A, Boughattas NA. 2003. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 20(6):1103‑1116. doi:10.1081/CBI-120025532.
   PubMed Web of Science ®Google Scholar
• Kobuchi S, Ito Y, Sakaeda T. 2017. Population pharmacokinetic-pharmacodynamic modeling of 5-fluorouracil for toxicities in rats. Eur J Drug Metab Pharmacokinet. 42(4):707–718. doi:10.1007/s13318-016-0389-3.
   PubMed Web of Science ®Google Scholar
• Koohi-Hosseinabadi O, Ranjbar Z, Sepehrimanesh M, Tadbir AA, Poorbaghi SL, Bahranifard H, Tanideh N, Koohi-Hosseinabadi M, Iraji A. 2017. Biochemical, hematological, and pathological related healing effects of Elaeagnus angustifolia hydroalcoholic extract in 5-fluorouracil-induced oral mucositis in male golden hamster. Environ Sci Pollut Res. 24(31):24447‑24453. doi:10.1007/s11356-017-0137-5.
   PubMed Web of Science ®Google Scholar
• Kuzel T, Esparaz B, Green D, Kies M. 1990. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 65(4):885–889. doi:10.1002/1097-0142(19900215)65:4<885:aid-cncr2820650410>3.0.co;2-h.
   PubMed Web of Science ®Google Scholar
• Launay M, Ciccolini J, Rodallec A, Fournel C, Duffaud F, Salas S, Lacarelle B. 2017. Upfront dpd deficiency detection to secure 5-fu administration: part 1-where do we stand? Clin Cancer Drugs. 4(2):74–81. doi:10.2174/2212697X04666170531080625.
   Google Scholar
• Launay M, Pourroy B, Ciccolini J. 2018. Gestion des toxicités précoces sévères au 5-fluorouracile: point sur le uridine triacetate (Vistogard®). Pharm Hosp Clin. 53(4):354‑358. doi:10.1016/j.phclin.2018.04.004.
   Google Scholar
• Lee JJ, Beumer JH, Chu E. 2016. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 78(3):447–464. doi:10.1007/s00280-016-3054-2.
   PubMed Web of Science ®Google Scholar
• Lévi F. 2002. From circadian rhythms to cancer chronotherapeutics. Chronobiol Int. 19(1):1–19. doi:10.1081/cbi-120002676.
   PubMed Web of Science ®Google Scholar
• Lévi F. 2003. Circadian rhythms in 5-fluorouracil pharmacology and therapeutic applications. Fluoropyrimidines in Cancer Therapy. 208:107–128. doi:10.1007/978-1-59259-337-8_7.
   Google Scholar
• Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declère A, et al. 1992. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 69(4):893–900. doi:10.1002/1097-0142(19920215)69:4<893:AID-CNCR2820690410>3.0.CO;2-X.
   PubMed Web of Science ®Google Scholar
• Levin J, Cocault L, Demerens C, Challier C, Pauchard M, Caen J, Souyri M. 2001. Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response. Blood. 98(4):1019‑1027. doi:10.1182/blood.v98.4.1019.
   PubMed Web of Science ®Google Scholar
• Lincolnii David W, Hrushesky William JM, Wood Patricia A. 2000. Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer. 88(3):479–485. doi:10.1002/1097-0215(20001101)88:3<479:AID-IJC23>3.0.CO;2-Z.
   PubMed Web of Science ®Google Scholar
• Luo L, Zhang J, Tang H, Zhai D, Huang D, Ling L, Wang X, Liu T, Zhang Q, Zhang Z, et al. 2020. LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. Cell Death Dis. 11(5):329. doi:10.1038/s41419-020-2557-2.
   PubMed Web of Science ®Google Scholar
• Maeda K, Shibutani M, Otani H, Fukuoka T, Iseki Y, Matsutani S, Nagahara H, Inoue T, Tachimori A, Nishii T, et al. 2018. Neoadjuvant radiotherapy with capecitabine plus bevacizumab for locally advanced lower rectal cancer: results of a single-institute phase II study. Anticancer Res. 38(7):4193‑4197. doi:10.21873/anticanres.12713.
   Web of Science ®Google Scholar
• Mak SSS, Hui PE, Wan WMR, Yih CLP. 2020. At-home chemotherapy infusion for patients with advanced cancer in Hong Kong. Hong Kong J Radiol. 23(2):122. doi:10.12809/hkjr2017181.
   Web of Science ®Google Scholar
• Mohd-Zahid MH, Mohamud R, Abdullah CAC, Lim J, Alem H, Hanaffi WNW, Iskandar ZA. 2020. Colorectal cancer stem cells: a review of targeted drug delivery by gold nanoparticles. RSC Adv. 10(2):973‑985. doi:10.1039/C9RA08192E.
   Web of Science ®Google Scholar
• Myers CE, Collins JM. 1983. Pharmacology of intraperitoneal chemotherapy. Cancer Invest. 1(5):395–407. doi:10.3109/07357908309048508.
   PubMed Web of Science ®Google Scholar
• Nelson W, Tong YL, Lee JK, Halberg F. 1979. Methods for cosinor-rhythmometry. Chronobiologia. 6(4):305–323.
   PubMedGoogle Scholar
• Niu Y, Fan X, Wang Y, Lin J, Hua L, Xiaobo L, Qian R, Chao L. 2022. Genome-wide CRISPR screening reveals pyrimidine metabolic reprogramming in 5-fu chronochemotherapy of colorectal cancer. Front Oncol Sec Cancer Mol Targets Thera. 12. doi:10.3389/fonc.2022.949715.
   Google Scholar
• Ohdo S. 2002. Development of new chronopharmacotherapies based on biological rhythm. Yakugaku Zasshi. 122(12):1059‑1080. doi:10.1248/yakushi.122.1059. Japanese.
   PubMed Web of Science ®Google Scholar
• Ohkura N, Oishi K, Sekine Y, Atsumi G, Ishida N, Matsuda J, Horie S. 2007. Comparative study of circadian variation in numbers of peripheral blood cells among mouse strains: unique feature of C3H/HeN mice. Biol Pharm Bull. 30(6):1177‑80. doi:10.1248/bpb.30.1177.
   Web of Science ®Google Scholar
• O’Neill JS, Reddy AB. 2011. Circadian clocks in human red blood cells. Nature. 469:498–503.
   PubMed Web of Science ®Google Scholar
• Patil AA, Kengar MD, Mane SA, Wagmare SA, Nirmale DM. 2020. Chronopharmacology: a great future for the medicines. Int J Sci Dev Res. 5(2):284–293.
   Google Scholar
• Petit E, Milano G, Lévi F, Thyss A, Bailleul F, Schneider M. 1988. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 48(6):1676–1679.
   PubMed Web of Science ®Google Scholar
• Piso RJ, Kriz K, Desax MC. 2011. Severe Isoniazid Related Sideroblastic Anemia. Hematol Rep. 3(1):e2. doi:10.4081/hr.2011.e2.
   PubMedGoogle Scholar
• Refinetti R. 2020. Circadian rhythmicity of body temperature and metabolism. Temperature. 7(4):321–362. doi:10.1080/23328940.2020.1743605.
   Google Scholar
• Reinberg A, Ashkenazi I. 2003. Concepts in human biological rhythms. Dialogues Clin Neurosci. 5(4):327–342. doi:10.31887/DCNS.2003.5.4/areinberg.
   PubMedGoogle Scholar
• Sagar SJ, Shashi PS, Yatendra S, Dakshina G, Preeti S, Saumya G, Ankit S, Akash S 2017. Chronopharmacology: recent advancements in the treatment of diabetes mellitus through chronotherapy. International Journal of Pharmacy & Pharmaceutical Research.Human. 9(2):87–99.
   Google Scholar
• Sayre RS, Barr JW, Bailey EM. 2012. Accidental and experimentally induced 5-fluorouracil toxicity in dogs. J Vet Emerg Crit Care (San Antonio). 22(5):545‑549. doi:10.1111/j.1476-4431.2012.00783.x.
   PubMed Web of Science ®Google Scholar
• Scheer FA, Michelson AD, Frelinger AL, Evoniuk H, Kelly EE, McCarthy M, Doamekpor LA, Barnard MR, Shea SA. 2011. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. Plos One. 6(9):e24549. doi:10.1371/journal.pone.0024549.
   PubMed Web of Science ®Google Scholar
• Shehatta NH, Okda TM, Omran GA, Abd-Alhaseeb MM. 2022. Baicalin; a promising chemopreventive agent, enhances the antitumor effect of 5-FU against breast cancer and inhibits tumor growth and angiogenesis in Ehrlich solid tumor. Biomed Pharmacother. 146:112599. doi:10.1016/j.biopha.2021.112599.
   PubMed Web of Science ®Google Scholar
• Souayed N, Chennoufi M, Boughattas F, Hassine M, Ben Attia M, Aouam K, Reinberg A, Boughattas NA. 2015. Circadian-time dependent tolerance and haematological toxicity to Isoniazid in murine. Biomed Pharmacother. 71:233‑239. doi:10.1016/j.biopha.2015.02.026.
   PubMed Web of Science ®Google Scholar
• Soveri LM, Hermunen K, Gramont A, Poussa T, Quinaux E, Bono P, André T, Österlund P. 2014. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: is efficacy an impact of toxicity? Eur J Cancer. 50(17):2966–2974. doi:10.1016/j.ejca.2014.08.017.
   PubMed Web of Science ®Google Scholar
• Stevenson TJ, Liddle TA, Stewart C, Marshall CJ, Majumdar G. 2022. Neural programming of seasonal physiology in birds and mammals: a modular perspective. Horm Behav. 142:105153. doi:10.1016/j.yhbeh.2022.105153.
   PubMed Web of Science ®Google Scholar
• Suenaga M, Akiyoshi T, Shinozaki E, Fujimoto Y, Matsusaka S, Konishi T, Nagayama S, Fukunaga Y, Kawakami K, Yokokawa T, et al. 2018. A feasibility study of capecitabine and oxaliplatin for patients with stage II/III colon cancer -ACTOR study. Anticancer Res. 38(3):1741–1747. doi:10.21873/anticanres.12410.
   PubMed Web of Science ®Google Scholar
• Tanideh N, Namazi F, Andisheh Tadbir A, Ebrahimi H, Koohi-Hosseinabadi O. 2014. Comparative assessment of the therapeutic effects of the topical and systemic forms of Hypericum perforatum extract on induced oral mucositis in golden hamsters. Int J Oral Maxillofac Surg. 43(10):1286–1292. doi:10.1016/j.ijom.2014.05.013.
   PubMed Web of Science ®Google Scholar
• Terazono H, Hamdan A, Matsunaga N, Hayasaka N, Kaji H, Egawa T, Makino K, Shigeyoshi Y, Koyanagi S, Ohdo S. 2008. Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: a possible mechanism of chemotherapy-induced circadian rhythm disturbances. Biochem Pharmacol. 8(8):1616–1622. doi:10.1016/j.bcp.2008.01.011.
   Google Scholar
• Touitou Y, Reinberg A, Touitou D. 2017. Association between light at night, melatonin secretion, sleep deprivation, and the internal clock: health impacts and mechanisms of circadian disruption. Life Sci. 173:94–106. doi:10.1016/j.lfs.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Vaflard P, Ederhy S, Torregrosa C, André T, Cohen R, Lopez-Trabada D. 2018. La toxicité cardiaque des fluoropyrimidines: 5-fluorouracile, capécitabine, le composé S-1 et le trifluridine/tipiracil. Bull Cancer. 105(7–8):707–719. doi:10.1016/j.bulcan.2018.05.005. French.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB. 2004. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5fluorouracil. Euro J Cancer. 40(7):939–950. doi:10.1016/j.ejca.2003.12.004.
   PubMed Web of Science ®Google Scholar
• Wood PA, Du-Quiton J, You S, William JMH. 2006. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther. 5(8):2023–2033. doi:10.1158/1535-7163.MCT-06-0177.
   PubMed Web of Science ®Google Scholar